Control theory of aging and longevity for gerotherapeutic drug discovery: state space, vector fields, modalities, safety, and the minimum safe cost of functional restoration.

Alex Zhavoronkov^1,2,3,4,5, Bud Mishra⁶

¹Insilico Medicine Hong Kong Ltd., Hong Kong SAR, China.

²Insilico Medicine Shanghai Ltd., Pudong 201203, Shanghai, China.

³Insilico Medicine AI Ltd., Masdar, Abu Dhabi, UAE.

⁴Insilico Medicine US Inc., Cambridge, MA 02138, USA.

⁵Buck Institute for Research on Aging, Novato, CA 94945, USA.

⁶Courant Institute School of Mathematics, Computer and Data Sciences, New York University, New York, NY 10012, USA.

PubMed DOI

Abstract

Existing aging theories describe what changes with age but do not prescribe how to intervene. We propose a control-theoretic framework that is not merely descriptive but prescriptive: it specifies which intervention, at which dose and sequence, under which safety constraints, will restore a measured biological state to a functional region. Aging is defined as progressive loss of safe controllabili…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.